Novo Nordisk (NVO) Stock Rises 6% After Q3 Beat and Higher 2026 Outlook

TLDR Novo Nordisk ADRs jumped 6.1% to $42.64 before the opening bell Wednesday. Wegovy pill sales hit 5.39 billion Danish krone, topping the 4.55 billion expected. Adjusted operating profit reached 31.7 billion crowns, ahead of the 28.7 billion forecast. The 2026 outlook now calls for adjusted sales and profit between negative 2% and 2% growth. Jefferies said pricing tailwinds flattered the sales beat and rates the stock “hold.” Novo Nordisk (NVO) stock jumped in early trading Wednesday after the drugmaker beat third-quarter estimates and raised its 2026 outlook. ADRs rose 6.1% to $42.64 before the opening bell. Novo Nordisk A/S, NVO They closed Tuesday at $40.19. The stock was down 21% for the year at that point.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to CoinCentral.